

86/01/70



HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Attorney Docket No.	GSF98-02 A
First Named Inventor or Application Identifier	Walter H. Gunzburg
Express Mail Label No.	EM012187121US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. Specification [Total Pages 38]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to microfiche Appendix
 - Background of the Invention
 - Summary of the Invention
 - Brief Description of the Drawings
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) [Total Sheets 13] 1
4. Oath or Declaration/POA [Total Pages]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 C.F.R. 1.63(d))
(for continuation/divisional with Box 17 completed)
[NOTE Box 5 below]
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: PCT /US96/04447

18. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label		21005	or <input type="checkbox"/> Correspondence address below
NAME	David E. Brook, Esq.		
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.		
ADDRESS	Two Militia Drive		
CITY	Lexington	STATE	MA
COUNTRY	USA	TELEPHONE	(781) 861-6240
ZIP CODE	02173		
FAX	(781) 861-9540		

Submitted by Typed or Printed Name	Anne J. Collins	Reg. Number	40,564
Signature	<i>Anne J. Collins</i>	Date	<i>April 10, 1998</i>

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

FEE TRANSMITTAL FOR PATENT APPLICATIONS		Attorney Docket Number	GSF98-02A	
		Application Number		
		First Named Inventor	Walter H. Gunzburg	

CLAIM CALCULATION (includes any preliminary amendment)

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	32 - 20 =	12	x \$ 22 =	\$ 264.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	1 - 3 =	0	x \$ 82 =	\$ 0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ 270 =	\$
				BASIC FEE (37 CFR 1.16(a))	\$ 790
				Total of above Calculations =	\$ 1054.00
	Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27, 1.28) =				\$
				TOTAL =	\$ 1054.00
	Surcharge - Fee for Late Filing of Declaration (37 C.F.R. 1.16(e)) =				\$
	Petition for Extension of Time Fee (37 C.F.R. 1.17) =				\$
	Assignment Recordation Fee =				\$
				TOTAL =	\$ 1054.00

1. Small entity status:

- a. A small entity statement is enclosed
- b. A small entity statement was filed in the prior non-provisional application and such status is still proper and desired.
- c. Is no longer claimed.

2. A general authorization is hereby granted to charge deposit account number 08-0380 for any fees required under 37 CFR 1.16 and 1.17 in order to maintain pendency of this application. A copy of this authorization is enclosed for accounting purposes.

3. A check is enclosed for \$ 1054.00. Please charge \$ _____ to Deposit Account No. 08-0380.

4. Other:
.....

Submitted by Typed or Printed Name	Anne J. Collins	Reg. Number	40,564
Signature	<i>Anne J. Collins</i>	Date	<i>April 10, 1998</i>

Date: April 16/1998 Express Mail Label No. EM012187121015

Inventors: Walter H. Günzburg, Robert M. Saller and Brian Salmons
Attorney's Docket No.: GSF98-02A

RETROVIRAL VECTORS CARRYING SENESCENT CELL
DERIVED INHIBITORS 1 (SDI-1) OR ANTISENSE
SDI-1 NUCLEOTIDE SEQUENCES

RELATED APPLICATIONS

5 This application is a Continuation application of PCT/US96/04447 filed October 11, 1996 which claims priority to DK 1157/95 filed October 13, 1995. The contents of PCT/US96/04447 and DK 1157/95 are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

10 Dividing cells undergo a cyclical programmed that culminates in cell division. A normal event in this cell cycle programmed is the replication of the cellular DNA. Just prior to DNA synthesis, there is a pause to allow proof reading of the DNA, ensuring that any damage or mutations are repaired and not passed on to daughter cells. This checkpoint (GI) is regulated by programmed gene expression. A second, similar 15 checkpoint occurs later on after DNA synthesis, just before the cell divides into two new cells, presumably for the same purpose. Senescent or aged cells are permanently arrested at one of these checkpoints. Recently, Olivia Pereira-Smith, Jim Smith and colleagues have identified three cDNA's that cause growth arrest when transfected into

young, actively dividing cells (Noda, A., *et al.*, *Exp. Cell Res.*, 211:900-98 (1994)). Other groups have described SDI-1 as WAF1, CIP1; PIC1 and p21 (Harper, J.N., *et al.*, *Cell*, 75:805-816 (1993) ; El-Deiry, W.S., *et al.*, *Cell*, 75:817-825 (1993); Xiong, Y., *et al.*, *Nature*, 366:701-704 (1993); Hunter, T. *et al.*, *Cell*, 75:839-841 (1993)). This gene 5 plays a central role in cellular processes that have in common the loss of cell proliferation which implicates this gene as being involved in cell cycle control. SDI-1 has been shown to be overexpressed in senescent cells, quiescent cells or cultured primary cells undergoing crisis (Noda, A., *et al.*, *Exp. Cell Res.*, 211:900-98 (1994); Rubelj, I. and Pereira-Smith, O.M., *Exp. Cell Res.*, 211:82-89 (1994)), suggesting a role 10 in the maintenance of DNA synthesis inhibition (Johnson, M., *et al.*, *Mol. Carcinogen.*, 11:59-64 (1994)). Further, evidence has been presented suggesting that the SDI-1 mediated inhibition of DNA synthesis occurs via an inhibition of CDK (cyclin-dependent kinases) activity (Nakanishi, M., *et al.*, *Proc. Natl. Acad. Sci. USA*, 92:4352-4356 (1995)). These findings, together with the demonstration that SDI-1 can 15 inhibit cell growth of young dividing cells, suggests that this gene will be useful for gene therapy to inhibit the growth of rapidly proliferating cells in diseases or disorders such as restenosis, in which smooth muscle cells inappropriately divide, or various cancers.

In this respect, SDI-1 will be useful therapeutically to suppress the rapid 20 proliferation of tumor or tumorigenic cells, such as breast, lung, hepatic and glioma tumor cells. SDI-1 has also been described to have the ability to mediate the differentiation of cancer cells (malignant melanoma cells) into non-cancerous cells. Additional applications for SDI-1 in a therapeutic context include the inhibition of 25 endothelial cell replication (angiogenesis) to prevent neovascularizations of tumors, and to halt cell growth (WO-A1-95/06415).

SDI-1 induces a senescent or quiescent state in recipient cells and will therefore also be useful in the treatment of various age-related disorders, asthenia and cachexia, or other diseases or conditions in which rapid cellular proliferation is undesirable.

SDI-1 can also be used in combination with conventional chemotherapeutic agents in order to enhance the efficacy of chemotherapeutic agents. The premise of chemotherapy is that cancer cells grow more rapidly than normal cells, and hence are more sensitive to cytotoxic agents than normal cells. Many chemotherapeutic agents 5 exert their effect during a specific phase or set of phases of the cell cycle, and because only a fraction of tumor cells are in a specific phase at any given time, such drugs must generally be provided by repeated administration.

SDI-1 can be used to synchronize or maximize the percentage of cells that are in a particular phase of the cell cycle at the time of administering the chemotherapeutic 10 agent, and thereby provide a means to increase the effectiveness of chemotherapy.

Other diseases such as psoriasis, rheumatoid arthritis and restenosis can also be treated with SDI-1. The use of SDI-1 for the treatment of viral and microbial infections and several other disorders or diseases are described in WO-A1-95/06415.

Antisense sequences are nucleic acids (either DNA or RNA) whose sequence is 15 complementary to the sequence of a target mRNA molecule (or its corresponding gene) so that it is capable of hybridizing with/binding to the mRNA molecule (or gene) and thereby impairing (i.e. attenuating or preventing) the transcription of the gene into mRNA or the translation of the mRNA molecule into a gene product.

Antisense SDI-1 DNA sequences may thus be used to inhibit the production of 20 endogenous SDI-1 and thereby stimulate the proliferation of cells. Antisense SDI-1 DNA sequences may therefore be used to promote wound healing, angiogenesis, endothelial cell proliferation, recovery from burns or surgery or to restore atrophied tissue (WO-A1-95/06415). Antisense SDI-1 DNA sequences can also be used to immortalize cells and permit the establishment of permanent cell lines. Antisense 25 SDI-1 DNA sequences may also be used in research or to permit or facilitate the accumulation of large numbers of cells, as for organ tissue grafts or transplants, or they may be used to immortalize cells producing important biological molecules such as hormones, interferons, or growth factors.

Transcription of antisense SDI-1 DNA sequences in cells in combination with irradiation leads to an increase in cell death. Transcription of antisense SDI-1 DNA sequences may therefore also be useful for gene therapy for the treatment of diseases or disorders characterized by rapid cell proliferation, such as certain tumors as well as in 5 vascular diseases such as restenosis.

Retroviral vectors are suitable gene transfer vehicles for stable therapeutic gene delivery to rapidly dividing cells such as cancer cells, because most retroviral particles only infect dividing cells and not the surrounding non-dividing cells. Further, the retroviral vector integrates in the chromosomal DNA of dividing cells, thereby ensuring 10 the transmission of therapeutic genes to all daughter cells, if the original infected cell is proliferating. Retroviral vectors are therefore the ideal vector for the delivery of DNA sequences encoding polypeptides affecting the proliferation of cells, such as SDI-1, into cells.

SUMMARY OF THE INVENTION

15 It is an object of the present invention to provide retroviral vectors expressing SDI-1 DNA sequences, functional analogues, or fragments thereof, useful for the inhibition of cell proliferation, as well as retroviral vectors carrying antisense SDI-1 DNA sequences useful for enhancing cell proliferation.

It is a further object of the present invention to provide such retroviral vectors 20 wherein the SDI-1 DNA sequences, functional analogues, or fragments thereof, or antisense SDI-1 DNA sequences are under the transcriptional control of target cell specific regulatory elements or promoters, especially mammary cell specific regulatory elements or promoters, or X-ray inducible promoters.

Another object of the present invention is to provide recombinant retroviral 25 particles capable of delivering SDI-1 DNA sequences, functional analogues, or fragments thereof, or antisense SDI-1 DNA sequences to cells, and the use thereof for

the treatment of disorders or diseases characterized by rapidly proliferating cells, such as cancer and restenosis.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Primers A (SEQ ID NO: 1), B (SEQ ID NO: 2), and C (SEQ ID NO: 3) used for deletion of U3 of MLV and insertion of a SacII-Mlu polylinker in its place.

Figures 2A-2B: Construction of plasmid pSmaU3del.

Figures 3A-3B: Construction of plasmids pBAGNU3del and pCON6

Figures 4A-4B: Construction of plasmid pMMTV-BAG.

Figure 5: Primers D (SEQ ID NO: 4) and E (SEQ ID NO: 5) used for amplification of the U3-region of MMTV.

Figure 6: Plasmid pMMTV-BAG.

Figure 7: Retroviral vector cloning strategy for pLXS-SDI-1.

Figures 8A-8B: FACS analyzes for cell cycle distribution; the percentage of cells in G₁/G₀ phase (Figure 8A) and S phase (Figure 8B).

Figure 9: Retroviral vector cloning strategy for pLX125.IDS.

Figures 10A-10C: Survival of cells expressing antisense SDI-1 after radiation.

DETAILED DESCRIPTION OF THE INVENTION

The invention then, inter alia, comprises the following, alone or in combination:

A replication defective retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, or an antisense SDI-1 DNA sequence;

a retroviral vector as above carrying a DNA sequence encoding SDI-1;

a retroviral vector as above wherein the DNA sequence codes for amino acids 1 to 71 of SDI-1;

a retroviral vector as above wherein the DNA sequence codes for amino acids 42 to 58 of SDI-1;

a retroviral vector as above carrying a DNA sequence which is antisense to the SDI-1 gene;

5 a retroviral vector as above wherein the antisense SDI-1 DNA sequence is 10 to 30, preferably 15 to 24 nucleotides long and prepared according to the nucleotide sequence of the SDI-1 gene;

a retroviral vector as above wherein the antisense SDI-1 DNA sequence is antisense to nucleotides 75 to 93 of the DNA sequence encoding SDI-1;

10 a retroviral vector as above, wherein the vector comprises a 5' LTR region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence containing a regulatory element or a promoter, followed by the U5 and R region, characterized in that at least one of the coding sequences is a DNA sequence encoding SDI-1, a functional analogue thereof, or a fragment thereof, or an antisense SDI-1 DNA sequence 15 which is under transcriptional control of said regulatory element or promoter;

a retroviral vector as above wherein the DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, or the antisense SDI-1 DNA sequence is under transcriptional control of a target cell specific regulatory element or promoter or an X-ray inducible promoter;

20 a retroviral vector as above wherein the target cell specific regulatory element is selected from the WAP and MMTV regulatory elements;

a retroviral vector as above which is pLXS-SDI1;

a retroviral vector as above which is pLX125.IDS;

25 a packaging cell line harbouring:

a) a retroviral vector as above

b) at least one DNA construct coding for the proteins required for said retroviral vector to be packaged;

a packaging cell line as above which is of human origin;

encapsulated cells comprising a core containing packaging cells as above and a porous capsule wall surrounding said core, said porous capsule wall being permeable to the retroviral particles produced by said packaging cells;

encapsulated cells as above wherein said porous capsule wall consists of a

5 polyelectrolyte complex formed from counter charged polyelectrolytes;

a recombinant retroviral particle produced by culturing a packaging cell line as above harbouring a retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, under suitable conditions optionally followed by isolation of the recombinant retroviral particle produced;

10 a recombinant retroviral particle produced by culturing a packaging cell line as above harbouring a retroviral vector carrying an antisense SDI-1 DNA sequence under suitable conditions optionally followed by isolation of the recombinant retroviral particle produced;

a pharmaceutical composition comprising a recombinant retroviral particle as

15 above and a pharmaceutically acceptable carrier or diluent;

a pharmaceutical composition comprising a packaging cell line as above and a pharmaceutically acceptable carrier or diluent;

the use of a retroviral particle as above for the preparation of a medicament for the treatment of disorders or diseases responsive to the anti-proliferative activity of

20 SDI-1;

the use as above for the preparation of a medicament for the treatment of a cancer, or restenosis;

the use as above for the preparation of a medicament for the treatment of breast cancer;

25 the use of a retroviral particle as above for the preparation of a medicament for the treatment of a disorder or disease responsive to the proliferative activity of antisense SDI-1 DNA sequences;

the use as above for the preparation of a medicament for the treatment of cancer;

a method for introducing DNA sequences encoding SDI-1, a functional analogue, or a fragment thereof or an antisense SDI-1 DNA sequence into human cells *in vitro* or *in vivo* comprising infecting a target cell population with a retroviral particle as above;

5 a method for the treatment of a disorder or disease responsive to the antiproliferative activity of SDI-1 comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a retroviral particle as above;

a method as above wherein the disorder or disease is a cancer, or restenosis;

10 a method for the treatment of a disorder or disease responsive to the proliferative activity of antisense SDI-1 DNA sequences comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a retroviral particle as above;

15 a method as above wherein the disorder or disease is cancer, and the administration of the retroviral particle is combined with irradiation; and

a method as above wherein the recombinant retroviral particle is administered as an injection, or by implantation of a packaging cell line as above, or an encapsulated packaging cell line as above into the living animal body, including a human, nearby or at the site of the tumor.

20 The DNA sequence and the amino acid sequence of SDI-1 is described in WO-A1-95/06415. Active domains of SDI-1 are also described herein:

The SDI-1 polypeptide is 164 amino acids long, but deletion of the carboxy terminal portion of the SDI-1 molecule (amino acids 72-164) do not significantly affect the inhibitory effect of the polypeptide. The active domains of SDI-1 are therefore present within a peptide fragment containing amino acids 1 to 71. Active domains also comprises amino acids 42 to 47, 53 to 58 and 66 to 71. Deletion of amino acids 53 to 58 was found to result in the greatest loss of DNA synthesis inhibitory activity (50 % of full length DNA). Deletions of amino acids 42 to 47 and 66 to 71 also resulted in a loss

of inhibitory activity but to a much lesser extent. Deletion analysis have thus indicated that the critical region of SDI-1 polypeptide must lie between amino acids 42 to 71, and fine studies implicate that the region between amino acids 48 to 65 are critical for the negative growth effects of the gene.

5 Fragments of SDI-1 having a function or biological activity analogous to that of SDI-1 thus include the first 70 amino acids of SDI-1. Smaller fragments such as those containing SDI-1 amino acid residues: 5-70, 10-70, 15-70, 20-70, 25-70, 30-70, 35-70 or 40-70 and especially amino acids 42 to 71 may also be employed. Such fragments can easily be identified by cleaving SDI-1 nucleic acid molecules by mechanical or 10 preferably restriction endonuclease cleavage and thereby generate candidate fragments. Such fragments can then be provided to cells, and their capacity to inhibit DNA synthesis can be monitored.

Functional analogues of SDI-1 means analogues of SDI-1 which are chemically related to SDI-1 and have a function or biological activity analogous to that of SDI-1. 15 Such analogues include naturally and non-naturally occurring derivatives of SDI-1.

Non-naturally occurring functional analogues of SDI-1 can be identified by random mutation or site directed mutagenesis. Random mutation of target gene sequences to obtain mutant proteins having the desired characteristics have been described previously (Leatherbarrow, R.J., *Prot. Eng.*, 1:7-16 (1986); Knowles, J.R., 20 *Science*, 236:1252-1258 (1987); Shaw, W.V., *Biochem. J.*, 246:1-17 (1987); Gerit, J.A., *Chem. Rev.*, 87:1079-1105 (1987)). Alternatively, where a particular sequence alteration is desired, methods of site directed mutagenesis can be employed (Craig, C.S., *Science*, 228:291-297 (1985); Cronin, C.S. *et al.*, *Biochem.*, 27:4572-4579 (1988); Wilks, H.M. *et al.*, *Science*, 242:1541-1544 (1988)).

25 DNA sequences encoding SDI-1 and antisense SDI-1 DNA sequences can be isolated from the plasmid pSDII (Noda, A., *et al.*, *Exp. Cell Res.*, 211:900-98 (1994)).

An antisense SDI-1 DNA sequence means a DNA sequence which is complementary to the mRNA transcribed from the endogenous SDI-1 gene or a

fragment thereof (and which is transcribed into a mRNA which is complementary to the endogenous SDI-1 gene or a fragment thereof), and which is capable of hybridizing with/binding to the SDI-1 mRNA or endogenous SDI-1 gene and thereby inhibit the production of SDI-1.

5 In one embodiment of the invention, the antisense SDI-1 DNA sequence is a sequence which is transcribed into a mRNA which is complementary to the full length endogenous SDI-1 gene.

The antisense SDI-1 DNA sequence can also be a sequence which is transcribed into a mRNA which is complementary to a fragment of the endogenous SDI-1 gene.

10 Such antisense SDI-1 DNA sequences are preferably 15 to 250 nucleotides, or more preferred 10 to 30 nucleotides, and most preferred 15 to 24 nucleotides long and are preferably in accordance with the nucleotide sequence of SDI-1.

15 Such antisense SDI-1 DNA sequences may be obtained using solid phase oligonucleotide synthetic methods, however, more preferably, such molecules can be obtained via the polymerase-mediated, template-dependent extension of a primer molecule that is antisense to a fragment of an SDI-1 nucleic acid molecule.

According to the present invention a retroviral vector is constructed which carries DNA sequences encoding SDI-1, functional analogues of SDI-1, or fragments thereof, or antisense SDI-1 DNA sequences.

20 The use of retroviral vectors for gene therapy has received much attention and is currently the method of choice for the transferral of therapeutic genes in a variety of approved protocols both in the USA and in Europe (Kotani, H. *et al.*, *Human Gene Therapy*, 5:19-28 (1994)).

Retroviral vector systems consist of two components:

25 1) The retroviral vector itself is a modified retrovirus (vector plasmid) in which the genes encoding for the viral proteins (gag, pol, and/or env) have been replaced by therapeutic genes and marker genes to be transferred to the target cell. Such

a retroviral vector comprises a 5'LTR-region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences replacing the gag, pol and/or env coding sequences; and a 3'LTR-region of the structure U3-R-U5.

5 Since the replacement of the genes encoding for the viral proteins effectively cripples the virus it must be rescued by the second component in the system which provides the missing viral proteins to the modified retrovirus.

The second component is:

2) a cell line that produces large quantities of the viral proteins (gag, pol, and/or env), however lacks the ability to produce replication competent virus. This cell line is known as the packaging cell line and consists of a cell line transfected with DNA constructs (e.g. one or more plasmids) carrying the genes encoding the viral proteins enabling the modified retroviral vector to be packaged.

10 To generate the packaged vector, the retroviral vector is transfected into the packaging cell line. Under these conditions the modified retroviral genome including the inserted therapeutic and marker genes is transcribed from the retroviral vector and packaged into the modified retroviral particles (recombinant viral particles). These recombinant viral particles are then used to infect target cells in which the vector genome and any carried marker or therapeutic genes become integrated into the target cell's 15 DNA. A cell infected with such a recombinant viral particle cannot produce new vector virus since no viral proteins are present in these cells (the virus is replication defective). However the DNA of the vector carrying the therapeutic and marker genes is integrated 20 in the cell's DNA and can now be expressed in the infected cell.

25 Retroviral vector systems have been optimized to minimize the chance of replication competent virus being present. However it has been well documented that recombination events between components of the retroviral vector system can lead to

the generation of potentially pathogenic replication competent virus and a number of generations of vector systems have been constructed to minimize this risk of recombination (Reviewed in Salmons, B., and Günzburg, W.H., *Human Gene Therapy*, 4:129-141 (1993)).

5 A further consideration when considering the use of *in vivo* gene therapy, both from a safety stand point and from a purely practical stand point, is the targeting of retroviral vectors. It is clear that therapeutic genes carried by vectors should not be indiscriminately expressed in all tissues and cells, but rather only in the requisite target cell.

10 A number of retroviral vector systems have been previously described that should allow targeting of the retroviral vector (Salmons, B., and Günzburg, W.H., *Human Gene Therapy*, 4:129-141 (1993)). Most of these approaches involve either limiting the infection event to predefined cell types or using heterologous promoters to direct expression of linked heterologous therapeutic or marker genes to specific cell 15 types. Heterologous promoters are used which should drive expression of linked genes only in the cell type in which this promoter is normally active. These promoters are inserted, in combination with the marker or therapeutic gene, in the body of the retroviral vectors, in place of the gag, pol or env genes.

20 Retroviral vectors according to the invention also includes retroviral vectors based on Self Inactivating-Vectors (SIN) in which retroviral promoters are functionally inactivated in the target cell (WO-A1-94/29437). Further modifications of these vectors include the insertion of promoter gene cassettes within the LTR region to create double copy vectors (WO-A1- 89/11539). In both of these vectors the heterologous promoters is inserted either in the body of the vector, or in the LTR region, directly linked to the 25 therapeutic gene.

25 In a preferred embodiment of the invention the retroviral vector used is a retroviral vector of the ProCon type as described in WO-A1-95/ 07748:

The retroviral genome consists of an RNA molecule with the structure R-U5-gag-pol-env-U3-R. During the process of reverse transcription, the U5 region is duplicated and placed at the right hand end of the generated DNA molecule, whilst the U3 region is duplicated and placed at the left hand end of the generated DNA molecule.

5 The resulting structure U3-R-U5 is called LTR (Long Terminal Repeat) and is thus identical and repeated at both ends of the DNA structure or provirus (Varmus, H., *Science*, 240:1427-1435, (1988)). The U3 region at the left hand end of the provirus harbours the promoter and transcriptional regulatory sequences. This promoter drives the synthesis of an RNA transcript initiating at the boundary between the left hand U3 10 and R regions and terminating at the boundary between the right hand R and U5 region. This RNA is packaged into retroviral particles and transported into the target cell to be infected. In the target cell the RNA genome is again reverse transcribed as described above.

In the ProCon-vector the right-hand U3 region is altered, but the normal 15 left-hand U3 structure is maintained; the vector can be normally transcribed into RNA utilizing the normal retroviral promoter located within the left-hand U3 region. However the generated RNA will only contain the altered right-hand U3 structure. In the infected target cell, after reverse transcription, this altered U3 structure will be placed at both ends of the retroviral structure. If the altered region carries a polylinker 20 (see below) instead of the U3 region then any promoter, including those directing tissue specific expression such as the WAP promoter can be easily inserted. This promoter will then be utilized exclusively in the target cell for expression of linked genes carried by the retroviral vector. Additionally DNA segments homologous to one or more cellular sequences can be inserted into the polylinker for the purposes of gene targeting, 25 by homologous recombination.

Other means of directing gene expression to target tissue is to use target cell specific regulatory elements or promoters.

The target cell specific regulatory elements and promoters are selected from one or more elements of the group consisting of Whey Acidic Protein (WAP), Mouse Mammary Tumour Virus (MMTV), β -lactoglobulin and casein specific regulatory elements and promoters, pancreas specific regulatory elements and promoters including 5 carbonic anhydrase II and β -glucokinase regulatory elements and promoters, lymphocyte specific regulatory elements and promoters including immunoglobulin and MMTV lymphocytic specific regulatory elements and promoters and MMTV specific regulatory elements and promoters conferring responsiveness to glucocorticoid hormones or directing expression to the mammary gland.

10 The LTR regions are selected from at least one element of the group consisting of LTRs of Murine Leukaemia Virus (MLV), Mouse Mammary Tumour Virus (MMTV), Murine Sarcoma Virus (MSV), Simian Immunodeficiency Virus (SIV), Human Immunodeficiency Virus (HIV), Human T-cell Leukaemia Virus (HTLV), Feline Immunodeficiency Virus (FIV), Feline Leukaemia Virus (FeLV), Bovine 15 Leukaemia Virus (BLV) and Mason-PfizerMonkey virus (MPMV).

In a preferred embodiment, the retroviral vector according to the invention comprises a DNA encoding SDI-1, a functional analogue, or a fragment thereof, or antisense SDI-1 DNA sequence under transcriptional control of human mammary specific regulatory elements, such as the WAP or MMTV regulatory sequences. Such 20 retroviral vectors are useful for delivering the antiproliferative activity of SDI-1 to human mammary carcinoma cells, and will therefore be useful for the treatment of human mammary carcinoma. A great advantage of these retroviral vectors is that the retroviral particles can be spread in the blood stream similarly to metastazing tumour cells, which will make it possible to eliminate micrometastases long before they can be 25 detected by conventional methods.

The WAP regulatory element can be isolated from pWAP2-HGH (Günzburg, W.H., *Molecular Endocrinology*, 5: 123-133, (1991)). In a preferred embodiment the WAP regulatory element contains the 320 bp Xhol/XbaI fragment of the WAP promoter

region, and in a particularly preferred embodiment, the WAP regulatory element is the proximal 445 bp of the WAP promoter.

The MMTV U3-region can be isolated from the plasmid pBG102. In a particular, preferred embodiment the MMTV regulatory element comprises the U3 5 region of MMTV without the inverted repeats. Fragments of the MMTV promoter containing the 0.6 Kb PstI MMTV promoter fragment can also be used.

In another embodiment of the invention the retroviral vector according to the invention carries the DNA encoding SDI-1, a functional analogue, or a fragment thereof, or antisense SDI-1 DNA sequence under transcriptional control of X-ray 10 inducible promoters, such as those from the tissue plasminogen activator and EGR1 genes (for an overview see Fornace, *Ann. Rev. Genet.*, 26:507-526 (1992)).

The retroviral vector according to the invention can also carry a marker gene.

The marker carried by the viral vector can be, for example, genes which code for proteins such as β -galactosidase, neomycin, alcohol dehydrogenase, luciferase, 15 puromycin, hypoxanthine phosphoribosyl transferase (HPRT), hygromycin, secreted alkaline phosphatase and green or blue fluorescent proteins.

The retroviral vectors of the invention are based preferably either on a BAG vector (Price, J., D. Turner, and C. Cepko, *Proc. Natl. Acad. Sci. USA*, 84:156-160 1987) or an LXSN vector (Miller, A.D. and G.J. Rossman, *Biotechniques*, 7:980-990 20 (1989)).

The packaging cell line can be selected from an element of the group consisting of psi-2 (Mann, R., *et al. Cell*, 33:153-159 (1983)), psi-Crip (Danos, O. and Mulligan R.C., *Proc. Natl. Acad. Sci. USA*, 85:6460-6464 (1988)), psi-AM (Cone, R.D. and Mulligan, R.C., *Proc. Natl. Acad. Sci. USA*, 81:6349-6353 (1984)), GP+E-86 25 (Markowitz, D., *et al.*, *J. Virol.*, 62:1120-1124 (1988a)), PA317 (Miller, A.D. and Buttimore, C., *Mol. Cell. Biol.*, 6:2895-2902 (1986)), GP+envAM-12 (Markowitz, D., *et al.*, *Virology*, 167:400-406 (1988b)), Bosc 23, Bing (Pear, W.S. *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 8392-8396 (1993)) or FLYA1 3, FLYRD18 (Cosset, F.L., *et al.*, *J. Virol.*,

69:74309-7436 (1995)) or of any of these transfected with recombinant constructs allowing expression of surface proteins from other enveloped viruses. Such pseudotyped retroviral particles are described in PCT/EP96/01348.

In a particular preferred embodiment, the packaging cell line is made from 5 human cells, e.g. HT1080 cells (WO-A1-9621014), or 293 (Graham *et al.*, *J. Gen. Virol.*, 36:59 1977)) thereby allowing production of recombinant retroviruses that are capable of surviving inactivation by human serum.

Another embodiment of the invention envisages the alteration or partial deletion of at least one retroviral sequence required for the integration of the retrovirus.

10 According to the invention the term "polylinker" is used for a short stretch of artificially synthesized DNA which carries a number of unique restriction sites allowing the easy insertion of any promoter or DNA segment.

The term "heterologous" is used for any combination of DNA sequences that is not normally found intimately associated in nature.

15 Preservation and administration of Retroviral particles

Recombinant retrovirus which has been purified or concentrated may be preserved by first adding a sufficient amount of a formulation buffer to the media containing the recombinant retrovirus, in order to form an aqueous suspension. The formulation buffer is an aqueous solution that contains a saccharide, a high molecular 20 weight structural additive, and a buffering component in water. The aqueous solution may also contain one or more amino acids.

The recombinant retrovirus can also be preserved in a purified form. More specifically, prior to the addition of the formulation buffer, the crude recombinant retrovirus described above may be clarified by passing it through a filter, and then 25 concentrated, such as by a cross flow concentrating system (Filtron Technology Corp., Northborough, MA). Within one embodiment, DNase is added to the concentrate to digest exogenous DNA. The digest is then diafiltrated to remove excess media

components and establish the recombinant retrovirus in a more desirable buffered solution. The diafiltrate is then passed over a Sephadex S-500 gel column and a purified recombinant retrovirus is eluted. A sufficient amount of formulation buffer is added to this eluate to reach a desired final concentration of the constituents and to 5 minimally dilute the recombinant retrovirus, and the aqueous suspension is then stored, preferably at -70°C or immediately dried. As noted above, the formulation buffer is an aqueous solution that contains a saccharide, a high molecular weight structural additive, and a buffering component in water. The aqueous solution may also contain one or more amino acids.

10 The crude recombinant retrovirus can also be purified by ion exchange column chromatography. In general, the crude recombinant retrovirus is clarified by passing it through a filter, and the filtrate loaded onto a column containing a highly sulfonated cellulose matrix. The recombinant retrovirus is eluted from the column in purified form by using a high salt buffer. The high salt buffer is then exchanged for a more desirable 15 buffer by passing the eluate over a molecular exclusion column. A sufficient amount of formulation buffer is then added, as discussed above, to the purified recombinant retrovirus and the aqueous suspension is either dried immediately or stored, preferably at -70°C.

20 The aqueous suspension in crude or purified form can be dried by lyophilisation or evaporation at ambient temperature. Specifically, lyophilisation involves the steps of cooling the aqueous suspension below the glass transition temperature or below the eutectic point temperature of the aqueous suspension, and removing water from the cooled suspension by sublimation to form a lyophilised retrovirus. Once lyophilised, the recombinant retrovirus is stable and may be stored at -20°C to 25°C, as discussed in 25 more detail below.

Within the evaporative method, water is removed from the aqueous suspension at ambient temperature by evaporation. Water can also be removed through spray drying.

The aqueous solutions used for formulation, as previously described, are composed of a saccharide, high molecular weight structural additive, a buffering component, and water. The solution may also include one or more amino acids. The combination of these components act to preserve the activity of the recombinant 5 retrovirus upon freezing and lyophilization, or drying through evaporation.

The high molecular weight structural additive aids in preventing viral aggregation during freezing and provides structural support in the lyophilised or dried state. Within the context of the present invention, structural additives are considered to be of "high molecular weight" if they are greater than 5000 m.w. A preferred high 10 molecular weight structural additive is human serum albumin.

The amino acids, if present, function to further preserve viral infectivity upon cooling and thawing of the aqueous suspension. In addition, amino acids function to further preserve viral infectivity during sublimation of the cooled aqueous suspension and while in the lyophilised state.

15 The buffering component acts to buffer the solution by maintaining a relatively constant pH. A variety of buffers may be used, depending on the pH range desired, preferably between 7.0 and 7.8.

Aqueous solutions for the formulation of recombinant retroviruses are described in detail in WO-A2-96121014.

20 In addition, it is preferable that the aqueous solution contain a neutral salt which is used to adjust the final formulated recombinant retrovirus to an appropriate iso-osmotic salt concentration.

Lyophilized or dehydrated retroviruses may be reconstituted using a variety of substances, but are preferably reconstituted using water. In certain instances, dilute salt 25 solutions which bring the final formulation to isotonicity may also be used. In addition, it may be advantageous to use aqueous solutions containing components known to enhance the activity of the reconstituted retrovirus. Such components include cytokines, such as IL-2, polycations, such as prolamine sulfate, or other components

which enhance the transduction efficiency of the reconstituted retrovirus. Lyophilized or dehydrated recombinant retrovirus may be reconstituted with any convenient volume of water or the reconstituting agents that allow substantial, and preferably total solubilization of the lyophilized or dehydrated sample.

5 Recombinant retroviral particles may be administered to a wide variety of locations including, for example, into sites such as an organ or to the site of a tumor. Within other embodiments, the recombinant retrovirus may be administered orally, intravenously, buccal/sublingual, intraperitoneally, or subcutaneously. The daily dosage depends upon the exact mode of administration, form in which administered, the
10 indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician in charge.

15 The routes of administration described herein may be accomplished simply by direct administration using a needle, catheter or related device. In particular, within certain embodiments of the invention, one or more dosages may be administered directly.

20 In another embodiment of the invention a cell line producing retroviral particles according to the invention, is encapsulated in a porous membrane which is permeable to the viral particles produced (Stange, J., *et al.*, *Biomat. Art. Cells & Immob. Biotech.* 21:343-352 (1993) and UK patent application 2 135 954)).

Upon implantation, vector virus is released but the capsule material protects the virus producing cells from the immune system.

25 The encapsulated cells according to the invention can be prepared for example by suspending the cells in an aqueous solution of a polyelectrolyte (e.g. selected from sulphate group-containing polysaccharides or polysaccharide derivatives or of sulphonate group containing synthetic polymers), whereafter the suspension in the form of preformed particles is introduced into a precipitation bath containing an aqueous

solution of a counter-charged polyelectrolyte (such as for example a polymer with quaternary ammonium groups).

Sulphate group-containing polysaccharides or polysaccharide derivatives includes cellulose sulphate, cellulose acetate sulphate, carboxymethylcellulose sulphate, 5 dextran sulphate or starch sulphate in the form of a salt, especially a sodium salt. The sulphonate group-containing synthetic polymer can be a polystyrene sulphonate salt, preferably a sodium salt.

Polymers with quaternary ammonium groups includes polydimethyldiallylammonium or polyvinylbenzyl-trimethylammonium, in the form of 10 a salt thereof, preferably a chloride salt.

Such capsules are preferably prepared by suspending the cells of the invention in a solution containing 0.5-50%, preferably 2-5%, sodium cellulose sulphate and 5% fetal calf serum in buffered saline. This suspension is then dropped by a dispensing system (e.g., air-jet system or piezoelectric system) while stirring into a precipitation bath 15 containing 0.5%-50%, preferably 2-10%, or most preferred 3% polydimethyl-diallylammonium chloride in buffered saline. Capsule formation occurs within milliseconds and the capsules containing cells are kept in the precipitation bath for 30 seconds to 5 minutes and then washed. The rapidity of this method ensures that the cells are not unduly stressed during the whole procedure (Stange, J., *et al.*, *Biomat.* 20 *Art. Cells & Immob. Biotech.* 21:343-352 (1993)).

The encapsulated cells can be cultivated in a normal cell culture medium (the nature of which depends on the encapsulated cells) at standard conditions of humidity, temperature and C0₂ concentration. During this culture period, production of viral particles from the capsules into the cell culture medium can be demonstrated using 25 RT-PCR technology or by transfer of cell free (0.45 mm filtered) supernatant to target cells followed by the demonstration of viral infection by assay for the activity of marker proteins encoded by genes carried by the viral vector construct contained within the viral particle. If the marker gene carried by the viral vector is a gene conferring

resistance to a specific compound upon the target cell or the product of which is easily assayed on a cell to cell basis (e.g., green or blue fluorescent protein), the titre of virus produced by the system can be ascertained.

After a suitable period in culture (normally not less than 1 hour and not 5 exceeding 30 days), the cell containing capsules can be surgically implanted either directly, or by injection using a syringe into various areas of the body including the breast.

The recombinant DNA methods employed in practicing the present invention are standard procedures, well known to those skilled in the art, and described in detail, for 10 example, in "Molecular Cloning" (Sambrook, J., E.F. Fritsch and T. Maniatis. 1989. Molecular Cloning. Cold Spring Harbor Laboratory Press, New York, USA) and in "A Practical Guide to Molecular Cloning" (Perbal, B. 1984. A Practical Guide to Molecular Cloning, John Wiley & Sons.).

The following examples will illustrate the invention further. The examples are 15 however in no way intended to limit the scope of the present invention as obvious modifications will be apparent, and still other modifications and substitutions will be apparent to anyone skilled in the art.

Example 1

Deletion of the U3 region and insertion of a polylinker

20 In the murine leukemia virus (MLV) retroviral vector known as BAG the β -galactosidase gene is driven by the promiscuous (*i.e.* non-tissue specific) MLV promoter in the U3 region of the LTR. According to the present invention a derivative of the BAG vector has been constructed in which the MLV promoter (U3) located within the 3'LTR except the inverted repeat has been deleted by PCR and replaced by a 25 polylinker. The BAG vector lacking the U3 is expressed from the MLV promoter (U3) within the 5'LTR when introduced into a packaging cell line. As a result of the rearrangements occurring in the retroviral genome during its life cycle, following

infection of its target cell, the polylinker will be duplicated at both ends of the retroviral genome as described in WO-A1-9607748. Thereby a retroviral vector can be constructed in which the expression of the β -galactosidase gene of BAG will be controlled by any heterologous promoter inserted into the polylinker.

5 As a template for PCR we used pBAGN a plasmid carrying a derivative of the BAG construct carrying only one LTR, created by an *Nhe*I digest of the original pBAG (Price, J., *et al.*, *Proc. Natl. Acad. Sci. USA*, 84:156-160 (1987)) followed by a self-ligation of the 7018bp fragment.

The 3' end of primer A is complementary to the R-region of the LTR (Figure 1).
10 The 5' extension contains an artificial (art.) polylinker and an artificial inverted repeat (IR(art)). Primer B is complementary to the U5 region of the LTR (Figure 1). After 35 cycles of annealing at 47°C and extension at 60°C, a 140 bp product was obtained, which was used as a template for the second PCR. In this reaction a *Clal*-site and an artificial (+)PBS was added 5' of the IR-region using primer C (Figure 1) in
15 combination with primer B. Annealing was carried out at 53°C and extension at 72°C. After 35 cycles a 163bp product was obtained, which was digested with *Clal* and *Sma*I and ligated to a 2722bp *Clal/Sma*I fragment of pSmaI (a derivate of pBAG (=pBAG complete) prepared by digestion with *Sma*I followed by a self ligation of the 3341 bp fragment) (Figures 2A-2B). The resulting plasmid pSmaU3del (2792bp) was linearized
20 by a *Sma*I digest and ligated to the 3677bp *Sma*I fragment of pBAGN (Figures 3A-3B) to give the plasmid pBAGNU3del (6469bp). Deletion of the U3 region was confirmed by sequencing from the *Clal*-site into the U5-region using pSmaU3del as a template.

A *Clal/Spel* (322bp) fragment containing the U3 deleted LTR was ligated to a *Clal/Nhe*I fragment of pBAGNB (created by self ligation of a 3946bp BamHI fragment of pBAGN) to give the plasmid pCON6 (4069bp) (Figures 3A-3B). This plasmid carrying a full U3-minus retroviral vector was used as a basis for further cloning using the inserted polylinker containing the restriction sites *Sac*I and *Mlu*I.

According to the principle set forth above the MMTV U3-region has been inserted into the polylinker region or the modified BAG vector.

Example 2

Cloning of pMMTVgal

5 The Mouse Mammary Tumour Virus (MMTV) U3-Region (mtv-2) without the inverted repeats including a region that confers responsiveness to glucocorticoid hormones and a region containing an element that directs expression to the mammary gland was inserted into pCON6.

10 The U3 region of MMTV was amplified by PCR using the plasmid pBG102 (a plasmid containing the 3'LTR from mtv 2) as a template with primers D and E. The 3' end of primer D is complementary to the 5' end of the MMTV U3 region and carries a *SacI* site in its 5' extension (Figure 5). The 3' end of primer E is complementary to the 3' end of the MMTV U3 region and has a *MluI* site in its 5' extension (Figure 5).

15 After 35 cycles of annealing at 49°C and extension at 72°C, a 1229 bp product was obtained, digested with *SacI* and *MluI* and ligated to the *SacI/MluI* digested vector pCON6. The resulting plasmid pl25.6 (5305 bp) (Figures 4A-4B) was digested with *XbaI* and *HindIII* and the 4187 bp fragment ligated to the *XbaI/HindIII* 4190 bp fragment of pBAGN containing the β -galactosidase gene to give the plasmid 20 pMMTV-BAG (8377 bp) (Figures 4A-4B) in which the β -galactosidase gene is under transcriptional control of the MLV promoter after transfection, and under the MMTV promoter after infection (Figure 6).

Example 3

Construction of ProCon SDI retroviral vector.

25 The human SDI-1 CDNA carried in the plasmid PSDII (Noda, A., *et al.*, *Exp. Cell. Res.*, 211:90-98 (1994)) was isolated by PCR using two primers, SDln1: 5'-TATGGACGTCTCCCTGCCGAAGTCAGTT-3' (SEQ ID NO: 6) and SDln2:

5'-TAT**GGATCC**GGCAGAAGATGTAGAGCG-3' (SEQ ID NO: 7), carrying *Bam*HI and *Aat*II restriction sites (bold sequences) as extensions. The plasmid pMMTVBAG was digested with *Aat*II and *Bam*HI (Figure 7). The resulting 5kb vector containing fragment was ligated to the SDI fragment, creating the plasmid pL25.SDI (Figure 7). In order to extend the retroviral packaging signal, pL25.SDI was digested with *Aat*II and *Af*III and the resulting 4.9kb fragment was blunt ended and ligated to a 3.5kb blunt ended *Eco*RI/*Af*III fragment of pLXSN (Miller, A.D., & Rosman, G.J., *Biotechniques*, 7:980-990 (1989)), giving the plasmid pLXS-SDII (Figure 7).

Example 4

10 Transfections and Infections

Cell culture and growth assay:

The human bladder carcinoma derived cell line EJ (Parada, L.F., *et al.*, *Nature*, 297:474-478 (1982)), cat kidney derived CRFK (Crandell, R.A., *In vitro*, 9:176-185 (1973)) and PA317 retrovirus packaging cells (Miller, A.D. & Buttimore, C., *Mol. Cell. Biol.*, 6:2895-2902 (1986)) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS).

For growth studies 5,000 EJ or CRFK cells were plated in each well of a six well plate (Falcon) in DMEM containing 10% FCS either with or without 10^{-6} M dexamethasone. After 7 days the cells were fixed in methanol:acetic acid (3:1) and 20 stained with Giemsa (Fisher So-G-28).

Transfection:

PA317 packaging cells were seeded in a 10cm tissue culture dish at a density of 2×10^6 cells one day prior to lipofection and then lipofected with 4 mg of plasmid pLXS-SDII and 2 mg of pHCMV-G (Burns, J.C., *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:8033-8037 (1993)) using the lipofectamine kit from GIBCO/BRL according to the manufacturers' instructions. The cells were diluted 1:10 24 hours after transfection and

cultured in the usual medium containing additionally 400 mg/ml G418 (GIBCO/BRL). After 14 days colonies of G418 resistant cell clones were pooled to give a population of retroviral vector producing cells (125 SDI/PA317).

Infection:

5 Infections were performed essentially as described previously (Hornsby, P. J. & Salmons, B., *Protocols in cell and tissue culture Module 26D:2, D:2.1:2.5* (1994)). Briefly, 24 hour conditioned cell culture medium from 2×10^6 125SDI/PA317 cells was passed through 0.45m Millipore filters, polybrene added to a final concentration of 8 mg/ml and 2 ml used to infect 1×10^6 EJ cells in a 10 cm culture dish. After 4 hrs 10 incubation, 6 ml of cell culture medium (DMEM + 10% FCS) was added and the cells cultured overnight. The cells were then trypsinised and one fifth of the total amount of cells were seeded in a new culture dish. After 24 hrs, the cell culture medium was changed to DMEM + 10 % FCS containing 800 mg/ml G418 and 14 days later resistant cell clones were isolated.

15 The ability of dexamethasone to turn on SDI-1 expression and the resulting growth inhibition has been examined in various ways.

Example 5

Fluoroscence activated cell scanning of infected cell clones was also performed to determine the proportion of cells in various stages of the cell cycle.

20 Fluorescent activated cell scanning: 5×10^5 EJ cells were seeded into T-225 flasks and cultured in DMEM containing 3% FCS with or without 10^{-6} M dexamethasone. For serum starvation experiments, cells were kept in DMEM lacking FCS for 24 hrs before medium was changed to 3% FCS. To avoid growth inhibition due to cell-to-cell contact, cells were grown until they reached 40 - 50 % confluence.

25 For cell cycle analysis the DNA was stained according to the micronuclei method (Nusse, M., *et al.*, *Methods in Cell Biology*, 42:149 (1994)). In brief, cells were

trypsinized and washed once with phosphate buffered saline. 10^6 cells were resuspended in 1 ml of Solution 1 (10 mM NaCl, 3.4 mM Na-citrate, 10mg/ml RNase A, 0.3% Nonidet P-40 and 25 mg/ml ethidium bromide (EB)). After 60 min. incubation at room temperature, 1 ml of Solution 2 (0.07 mM citric acid, 0.25 M sucrose and 40 mg/l EB) was added. The FACS analyses were performed with a FACSCalibur (Becton Dickinson; excitation of EB with an argon laser, 488 nm; EB fluorescence was detected with a long pass filter (LP 640)). A first gate was set to exclude unspecific debris from nuclei according to side scatter and forward scatter. A gate in the Fluorescence 2 width-Fluorescence 2 area dot plot was used to exclude doublets. The DNA content was estimated using a Fluorescence 2 area histogram. Cell cycle distribution was analyzed using the MOD FIT LT program (Verity software house Inc.).

The results from this experiment are presented in the following Table:

Cell Cycle Phase	Cell Populations (% of total Cells)			
	Control	Control - D	SDI	SDI + D
G ₁ /G ₀	45.4	52.4	50.6	61
S	40.5	35.4	35.7	27
G2/M	14.1	12.2	13.7	12

EJ cells grown in the absence or presence of Dex show no significant difference in the percentage of cells in G₀/G₁, irrespective of whether the cells were serum starved (cf; 15 45.4% and 52.4%) or grown normally. In contrast the representative EJ SDI-1 clone 7 showed significantly more cells in G₀/G₁, when grown in the presence of Dex after serum starvation (61%) than in the absence of SDI-1 expression (50.6%). Similar significant differences were observed even when the cells were not previously serum starved and treated with Dex as compared to nontreated cells. The mean percentage of 20 cells in G₀/G₁, in different experiments is shown in Figure 8A. Whereas both Dex 25

treated and nontreated control cells as well as untreated SDI-1 vector infected cells all had between 40 and 53% of their cells in G₀/G₁, SDI-1 vector infected cells treated with Dex and thus expressing SDI-1 had between 55 and 62% in G₀/G₁. A commensurate reduction from 35-45% to 25-34% of the number of cells in the S phase could also be 5 observed after Dex induction of SDI-1 expression (Figure 8B). These results suggest that, irrespective of serum starvation, the induction of SDI-1 expression leads to an increased proportion of the cells in the G₀/G₁, phase of the cell cycle.

Example 6

A second therapeutic use of SDI-1 involves the expression of an antisense SDI-1 10 to reduce the expression of endogenous SDI-1. This will prevent cells pausing to check DNA integrity and repair of the DNA before new DNA synthesis begins in preparation for the next cell division. If cells expressing antisense SDI-1 are treated with DNA damaging agents such as mutagens, carcinogens or irradiation (e.g. gamma, U.V.), the efficiency of DNA damage repair will be severely reduced because the cell will not 15 pause to permit proof reading and repair. These cells will accumulate so much DNA damage that they are no longer viable.

Construction of ProCon IDS retroviral vector

The human SDI-1 cDNA carried in the plasmid pSDI-1 (5071 bp) (Noda, A., *et al.*, *Exp. Cell. Res.*, 211:90-98 (1994)) was isolated by digestion with *Bam*HI and *Bsp* 20 1407 (707 bp) and cloned in the antisense orientation (sticky ends) in the plasmid pLX125 (7812 bp) carrying U3 region of MMTV in place of the MLV U3 after digestion also with *Bam*HI and *Bsp* 1407 (7674 bp) (sticky ends). The resulting plasmid was named pLX125.IDS (8381 bp) (Figure 9).

pLX125 was prepared by ligation (sticky ends) of a 3545 bp *Af*III/*Bam*HI 25 fragment of pLXSN (Miller, A.D., & Rosman, G.J., *Biotechniques*, 7:980-990 (1989)) and a 4263bp *Af*III/ *Bam*HI fragment of p125.6 (Example 2, Figures 4A-4B). The

resulting *Af*III/*Af*III fragment was blunt ended with klenow and ligated to give the plasmid pLX125 (7812 bp).

Example 7

Transfection and Infection

5 For packaging, transfection and infection experiments, the human bladder carcinoma derived cell line EJ, cat kidney derived CK and PA317 retrovirus packaging cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS).

10 The packaging cells PA317 were seeded in a six well plate at a density of 5×10^5 cells one day prior to lipofection and then lipofected with 1mg of plasmid pLX125.IDS and 1 mg of PHCMV-G using the lipofectamine kit from GIBCO/BRL according to the manufacturers' instructions (125IDS/PA317).

15 Infections were performed essentially as described previously. Briefly, 48 hr conditioned cell culture medium from these 125IDS/PA317 cells was passed through 0.45 m Millipore filters, polybrene added to a final concentration of 8 mg/ml and 2 ml used to infect 5×10^5 EJ/CK cells in a 10 cm culture dish. After 5 hrs incubation, 6 ml of medium was added and the cells cultured overnight. The cells were then trypsinised and diluted 1:20. After 24 hrs the cell culture medium was changed to DMEM + 10% FCS containing 800mg/ml G418 for the EJ cells, 400mg/ml G418 for the CK cells and 20 14 days later resistant cell clones as well as populations were isolated.

For transfections 5×10^5 CK or EJ cells were seeded in a 6 cm dish 24 hrs prior to transfection and then transfected with 10mg of plasmid using the transfection kit from Pharmacia according to the manufacturers' instructions. After incubation for 14 hrs the cell were trypsinised and diluted 1:5. After 24 hrs the cell culture medium was 25 changed to DMEM containing 400 mg/ml G418 for the CK cells, 800 mg/ml G418 for the EJ cells and 14 days later resistant cell clones as well as populations were isolated.

Example 8

Growth properties of transfected cells.

Expression of IDS should prevent cells from stopping in the checkpoint and therefore the cells should progress through the cell cycle.

5 In order to test whether the induction of IDS expression is associated with enhanced proliferation, 5000 cells were plated in each well of a six well plate (Falcon) in DMEM containing 10% FCS either with or without 10-6 dexamethasone. After 7 days the cells were fixed in methanol:acetic acid (3:1) and stained with Giemsa (Fisher So-G-28).

10 Transfected CK cells showed increased growth, as compared to their nontreated counterparts. The slight increased proliferation with the LX1 25 vector shows a proliferative effect of transfections as has been previously observed (Günzburg, W.H., *et al.*, *Carcinogenesis*, 9:1849-1856 (1988)).

Example 9

15 A cell survival curve describes the relationship between the radiation dose and the proportion of cells that survive. The capability of a single cell to grow into a large colony, which can easily be seen with the naked eye, is a convenient proof that it has retained its reproductive integrity. The loss of this ability as a function of radiation dose is described by the dose survival curve.

20 Cells from an actively growing stock culture are prepared into a suspension by the use of trypsin, which causes the cells to round up and detach from the surface of the culture vessel. The number of cells of this suspension is counted. In this way, for example, 100 individual cells may be seeded into a dish. If this dish is incubated for 2 weeks, each single cell will divide many times and form a colony that is easily visible 25 with the naked eye, especially if it is fixed and stained. All cells comprising each colony are the progeny of a single ancestor. For a nominal 100 cells seeded into the dish, the number of colonies counted may be expected to be in the range of 50 to 90.

Ideally, it should be 100, but it seldom is for a variety of reasons, including suboptimal growth medium, errors and uncertainties in counting the cell suspension, and the trauma of trypsinization and handling. The term plating efficiency (PE) indicates the percentage of cells seeded that grow into colonies.

5 plating efficiency (PE) = colonies counted / cells seeded x 100

When a parallel dish is seeded with cells, exposed to a dose of 0 to 10 Gy of gamma-rays, and incubated for 2 weeks before being fixed and stained, then the following may be observed: (1) some of the seeded single cells are still single and have not divided; (2) some cells have managed to complete one or two divisions to form a 10 tiny abortive colony; and (3) some cells have grown into large colonies that differ little from the unirradiated controls, although they may vary more in size. In general, the surviving fraction is given by

surviving fraction (SF) = colonies gamma-ray counted/cells seeded x (PE/100).

Cell survival curves

15 Plating efficiency (PE): EJ, CK cells and infected or transfected cell populations were seeded at different cell densities in 50 ml flasks (Nunc, Denmark). (EJ and CK cells were cultured in DMEM containing 10% FCS, CK transfectants in DMEM containing 10% FCS and 400 mg/ml G418; Infected EJ cell clones in DMEM containing 10%FCS and 800 mg/ml G418.)

20 After two weeks incubation the cells were fixed in methanol:acetic acid (3:1), stained with Giemsa (Fischer So-G-28) and colonies were counted. Cell culture flasks were seeded with the number of cells that give around 70 colonies after two weeks incubation and exposed to different doses of gamma-ray irradiation (1-10 Gy, 1 Gy =

100 rads). Two weeks later the cell colonies were fixed and stained. Colonies were counted and the surviving fraction (SF) was determined.

The graphs (Figures 10A-10C) show a decreased survival for the LX125.IDS transfected as well for the LX125.IDS infected cells in comparison to the parental cells 5 and the transfected or infected cells with the LX125 vector alone, especially after irradiation with a dose till 1.5 Gy.

EQUIVALENTS

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that 10 various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the 15 scope of the claims.

CLAIMS

What is claimed is:

1. A retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, or an antisense SDI-1 DNA sequence.
- 5 2. A retroviral vector according to Claim 1 carrying a DNA sequence encoding SDI-1.
3. A retroviral vector according to Claim 1 wherein the DNA sequence codes for amino acids 1 to 71 of SDI-1.
4. A retroviral vector according to Claim 1 wherein the DNA sequence codes for 10 amino acids 42 to 58 of SDI-1.
5. A retroviral vector according to Claim 1 carrying a DNA sequence which is antisense to the SDI-1 gene.
- 15 6. A retroviral vector according to Claim 1 wherein the antisense SDI-1 DNA sequence is 10 to 30, preferably 15 to 24 nucleotides long and prepared according to the nucleotide sequence of the SDI-1 gene.
7. A retroviral vector according to Claim 6 wherein the antisense SDI-1 DNA sequence is antisense to nucleotides 75 to 93 of the DNA sequence encoding SDI-1.

8. A retroviral vector according to Claim 1, wherein the vector comprises a 5' LTR region of the structure U3-R-U5; one or more sequences selected from coding and noncoding sequences; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence containing a regulatory element or a promoter, followed by the U5 and R region, characterized in that at least one of the coding sequences is a DNA sequence encoding SDI-1, a functional analogue thereof, or a fragment thereof, or an antisense SDI-1 DNA sequence which is under transcriptional control of said regulatory element or promoter.

5

10 9. A retroviral vector according to Claim 1 wherein the DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, or the antisense SDI-1 DNA sequence is under transcriptional control of a target cell specific regulatory element or promoter or an X-ray inducible promoter.

15 10. A retroviral vector according to Claim 9 wherein the target cell specific regulatory element is the selected from the WAP and MMTV regulatory elements.

11. A retroviral vector according to Claim 10 which is pLXS-SDI1.

12. A retroviral vector according to Claim 10 which is pLX125.IDS.

13. A packaging cell line harbouring:

20 a) a retroviral vector according to Claim 1; and

b) at least one DNA construct coding for the proteins required for said retroviral vector to be packaged.

14. A packaging cell line according to Claim 13 which is of human origin.

15. Encapsulated cells comprising a core containing packaging cells according to Claim 13 and a porous capsule wall surrounding said core, said porous capsule wall being permeable to the retroviral particles produced by said packaging cells.

16. Encapsulated cells according to Claim 15 wherein said porous capsule wall consists of a polyelectrolyte complex formed from counter charged polyelectrolytes.

17. A recombinant retroviral particle produced by culturing a packaging cell line according to Claim 13 harbouring a retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, or a fragment thereof, under suitable conditions optionally followed by isolation of the recombinant retroviral particle produced.

18. A recombinant retroviral particle produced by culturing a packaging cell line according to Claim 13 harbouring a retroviral vector carrying an antisense SDI-1 DNA sequence under suitable conditions optionally followed by isolation of the recombinant retroviral particle produced.

19. A pharmaceutical composition comprising a recombinant retroviral particle according to Claim 17 and a pharmaceutically acceptable carrier or diluent.

20. A pharmaceutical composition comprising a packaging cell line according to Claim 13 and a pharmaceutically acceptable carrier or diluent.

21. The use or a retroviral particle according to Claim 17 for the preparation of a medicament for the treatment of disorders or diseases responsive to the anti-proliferative activity of SDI-1.

22. The use according to Claim 21 for the preparation of a medicament for the treatment of a cancer, or restenosis.

5 23. The use according to Claim 22 for the preparation of a medicament for the treatment of breast cancer.

24. The use of a retroviral particle according to Claim 18 for the preparation of a medicament for the treatment of a disorder or disease responsive to the proliferative activity of antisense SDI-1 DNA sequences.

10 25. The use according to Claim 24 for the preparation of a medicament for the treatment of cancer.

26. A method for introducing DNA sequences encoding SDI-1, a functional analogue, or a fragment thereof, or an antisense SDI-1 DNA sequence into human cells in vitro or in vivo comprising infecting a target cell population with a retroviral particle according to Claim 17.

15 27. A method for the treatment of a disorder or disease responsive to the antiproliferative activity of SDI-1 comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a retroviral particle according to Claim 17.

20

28. A method according to Claim 27 wherein the disorder or disease is a cancer, or restenosis.

29. A method for the treatment of a disorder or disease responsive to the proliferative activity of antisense SDI-1 DNA sequences comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a retroviral particle according to Claim 18.

30. A method according to Claim 29 wherein the disorder or disease is cancer, and the administration of the retroviral particle is combined with irradiation.

31. A method according to Claim 28 wherein the recombinant retroviral particle is administered as an injection, or by implantation of a packaging cell line harbouring:

10 a) a retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, a fragment thereof or an antisense SDI-1 DNA sequence; and

15 b) at least one DNA construct coding for the proteins required for said retroviral vector to be packaged into the living animal body, including a human, nearby or at the site of the tumor.

32. A method according to Claim 28 wherein the recombinant retroviral particle is administered as an injection, or by implantation of an encapsulated packaging cell line comprising encapsulated cells having a core containing packaging cells harbouring:

20

- a) a retroviral vector carrying a DNA sequence encoding SDI-1, a functional analogue, a fragment thereof or an antisense SDI-1 DNA sequence; and
- b) at least one DNA construct coding for the proteins required for said retroviral vector to be packaged

5 and a porous capsule wall surrounding said core, said porous capsule wall being permeable to the retroviral particles produced by the packaging cells, into the living animal body, including a human, nearby or at the site of the tumor.

RETROVIRAL VECTORS CARRYING SENESCENT CELL DERIVED
INHIBITORS 1 (SDI-1) OR ANTISENSE SDI-1 NUCLEOTIDE SEQUENCES

ABSTRACT OF THE DISCLOSURE

The present invention relates to retroviral vectors carrying DNA sequences
5 encoding SDI-1, functional analogues of SDI-1, or fragments thereof, or antisense
SDI-1 DNA sequences, and especially retroviral vectors carrying the SDI-1 or antisense
SDI-1 sequences under the transcriptional control of target cell specific regulatory
elements or promoters or X-ray inducible promoters. Further, the invention relates to
the use of such retroviral vectors for the production of recombinant retroviral particles
10 useful for the treatment of disorders or diseases responsive to the anti-proliferative
activity of SDI-1, or the proliferative activity of antisense SDI-1 sequences.




FIGURE 1




FIGURE 2A




FIGURE 2B

FIGURE 3A




FIGURE 3B




FIGURE 4A





FIGURE 4B






FIGURE 5

FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 8




FIGURE 9




FIGURE 10

A




FIGURE 10

B






FIGURE 10

C



United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

- 1 Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
 - All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11" Pages _____ do not meet these requirements.
 - Papers are not flexible, strong, smooth, non-shiny, durable, and white.
 - Papers are not typewritten or mechanically printed in permanent ink on one side.
 - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
 - Papers contain hand lettering.
- 2 Drawings are not in compliance and were not scanned because:
 - The drawings or copy of drawings are not suitable for electronic reproduction.
 - All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11"
 - Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
- 3 Page(s) _____ are not of sufficient clarity, contrast and quality for electronic reproduction
- 4 Page(s) _____ are missing.
- 5 OTHER NO DECLARATION